Multi-Center Randomized Controlled Clinical Trial of Sitz Bath Medications for Improving Symptoms After Hemorrhoidectomy

注册号:

Registration number:

ITMCTR2025001198

最近更新日期:

Date of Last Refreshed on:

2025-06-17

注册时间:

Date of Registration:

2025-06-17

注册号状态:

Registration Status:

补注册

Retrospective registration

注册题目:

坐浴药物改善痔术后症状随机对照多中心临床试验

Public title:

Multi-Center Randomized Controlled Clinical Trial of Sitz Bath Medications for Improving Symptoms After Hemorrhoidectomy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

坐浴药物改善痔术后症状随机对照多中心临床试验

Scientific title:

Multi-Center Randomized Controlled Clinical Trial of Sitz Bath Medications for Improving Symptoms After Hemorrhoidectomy

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

蔡梦涵

研究负责人:

谢振年

Applicant:

caimenghan

Study leader:

xiezheninan

申请注册联系人电话:

Applicant telephone:

17692361618

研究负责人电话:

Study leader's telephone:

13401185869

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

17692361618@163.com

研究负责人电子邮件:

Study leader's E-mail:

xiezhennian@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区西苑操场路1号

研究负责人通讯地址:

北京市海淀区西苑操场路1号

Applicant address:

No. 1 Xiyuan Caochang Road Haidian District Beijing

Study leader's address:

No. 1 Xiyuan Caochang Road Haidian District Beijing

申请注册联系人邮政编码:

Applicant postcode:

100091

研究负责人邮政编码:

Study leader's postcode:

100091

申请人所在单位:

中国中医科学院西苑医院

Applicant's institution:

Xiyuan Hospital of CACMS

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

No: 2021ABCP001

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

北京肛肠学会

Name of the ethic committee:

Beijing Society of Coloproctology

伦理委员会批准日期:

Date of approved by ethic committee:

2021/5/9 0:00:00

伦理委员会联系人:

黄小宴

Contact Name of the ethic committee:

huangxiaoyan

伦理委员会联系地址:

北京市丰台区云岗镇南里三号

Contact Address of the ethic committee:

No. 3 Nanli Yungang Town Fengtai District Beijing City China

伦理委员会联系人电话:

Contact phone of the ethic committee:

13811814491

伦理委员会联系人邮箱:

Contact email of the ethic committee:

Xuehui@med626.com

研究实施负责(组长)单位:

中国中医科学院西苑医院

Primary sponsor:

Xiyuan Hospital of CACMS

研究实施负责(组长)单位地址:

北京市海淀区西苑操场路1号

Primary sponsor's address:

No. 1 Xiyuan Caochang Road Haidian District Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市海淀区西苑操场路1号

市(区县):

海淀区

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院西苑医院

具体地址:

北京市海淀区西苑操场路1号

Institution
hospital:

Xiyuan Hospital of CACMS

Address:

No. 1 Xiyuan Caochang Road Haidian District Beijing

经费或物资来源:

中国中医科学院科技创新工程项目

Source(s) of funding:

Scientific and Technological Innovation Project of the China Academy of Chinese Medical Sciences

研究疾病:

Ⅲ、Ⅳ度内痔、混合痔、外痔

研究疾病代码:

Target disease:

grades III/IV internal hemorrhoids mixed hemorrhoids or external hemorrhoids

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

目前临床上治疗痔术后疼痛等症状的方法很多,但每种方法都有自身的优势所在,但也有各自的不足,比如口服镇痛药物对中等疼痛效果不足、止痛栓剂的不良反应问题以及注射镇痛药物的用药方式和不良反应等。本次研究希望通过痛血康疗效验证来给患者提供快速、有效、安全的治疗方案,同时改善患者生活质量及减轻经济负担。本研究旨在验证痛血康坐浴在治疗Ⅲ、Ⅳ度内痔、混合痔、外痔手术后并发症的有效性及安全性,为坐浴疗法提供安全、有效的药物,从而给肛肠疾病患者提供一种安全、有效、方便的防治方案。

Objectives of Study:

Currently there are many clinical methods for treating postoperative pain and other symptoms following hemorrhoid surgery. Each method has its own advantages but also certain limitations. For example oral analgesics may be insufficient for moderate pain pain-relief suppositories can have adverse effects and injectable analgesics pose challenges in administration and potential side effects. This study aims to validate the efficacy of Tongxuekang to provide patients with a fast effective and safe treatment option while improving their quality of life and reducing financial burden. Specifically the study seeks to assess the effectiveness and safety of Tongxuekang sitz baths in managing postoperative complications of grade III and IV internal hemorrhoids mixed hemorrhoids and external hemorrhoids. By verifying the efficacy of sitz bath therapy this research aims to offer a safe effective and convenient prevention and treatment option for patients with anorectal diseases.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

临床诊断为Ⅲ、Ⅳ度内痔、混合痔、外痔并经手术治疗后具疼痛、出血、坠胀、创缘水肿并发症的患者;年龄 18-75 岁,性别不限;取得病人或监护人的知情同意并签字。

Inclusion criteria

Patients clinically diagnosed with grade III or IV internal hemorrhoids mixed hemorrhoids or external hemorrhoids who have undergone surgical treatment and present with postoperative complications such as pain bleeding distension and wound edge edema; aged 18 to 75 years regardless of gender; with informed consent obtained from the patient or their guardian and a signed consent form.

排除标准:

预后恶劣,如恶性肿瘤晚期、严重慢性各系统疾患者;证实有其他肛肠疾病的患者;妊娠及哺乳期妇女;依从性差,无法完成或拒绝完成随访者;血小板异常、肾功能指标异常、肝功能指标超出两倍以上的患者;过敏体质,有药物、食物过敏史或已知对本药组成成分过敏者;近 3 个月参加过其它临床试验者;研究者认为不宜入选的其他原因

Exclusion criteria:

Patients with poor prognosis such as those in the late stages of malignant tumors or with severe chronic diseases affecting various systems; patients diagnosed with other anorectal diseases; pregnant or breastfeeding women; individuals with poor compliance who are unable or unwilling to complete follow-up; patients with abnormal platelet levels abnormal renal function indicators or liver function indicators exceeding twice the normal range; individuals with allergic constitutions a history of drug or food allergies or known allergies to the components of the study medication; those who have participated in other clinical trials within the past three months; and other conditions deemed unsuitable for inclusion by the researchers.

研究实施时间:

Study execute time:

From 2021-05-20

To      2022-02-28

征募观察对象时间:

Recruiting time:

From 2021-06-01

To      2022-02-28

干预措施:

Interventions:

组别:

试验组

样本量:

300

Group:

trial group

Sample size:

干预措施:

术后常规换药治疗+痛血康胶囊1.6g与40℃左右温水1000ml混合药液坐浴,2次/天,每次15分钟

干预措施代码:

Intervention:

Postoperative routine wound care treatment + sitz bath with a mixture of 1.6g Tongxuekang capsules and 1000ml warm water at approximately 40°C, twice daily, for 15 minutes per session.

Intervention code:

组别:

对照组

样本量:

300

Group:

control group

Sample size:

干预措施:

术后常规换药治疗+碘伏30ml与40℃左右温水1000ml混合药液坐浴,2次/天,每次15分钟

干预措施代码:

Intervention:

Postoperative routine wound care treatment + sitz bath with a mixture of 30ml povidone-iodine and 1000ml warm water at approximately 40°C, twice daily, for 15 minutes per session.

Intervention code:

样本总量 Total sample size : 600

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu

City:

单位(医院):

东南大学附属中大医院

单位级别:

三甲医院

Institution/hospital:

Department of Anorectal Surgery Zhongda Hospital Southeast University

Level of the institution:

Tertiary Grade A Hospital

国家:

中国

省(直辖市):

辽宁省

市(区县):

大连市

Country:

China

Province:

Dalian

City:

单位(医院):

大连市中心医院

单位级别:

三甲医院

Institution/hospital:

Department of Anorectal Surgery Dalian Municipal Central Hospital

Level of the institution:

Tertiary Grade A Hospital

国家:

中国

省(直辖市):

上海市

市(区县):

南充市

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第六人民医院

单位级别:

三甲医院

Institution/hospital:

Shanghai Sixth People's Hospital

Level of the institution:

Tertiary Grade A Hospital

国家:

中国

省(直辖市):

北京

市(区县):

北京市 / 市辖区 / 海淀区

Country:

China

Province:

Beijing

City:

/ /

单位(医院):

中国中医科学院西苑医院

单位级别:

三甲医院

Institution/hospital:

Xiyuan Hospital of CACMS

Level of the institution:

Tertiary Grade A Hospital

国家:

中国

省(直辖市):

福建省

市(区县):

福州市

Country:

China

Province:

Fujian

City:

/ /

单位(医院):

福建中医药大学附属人民医院

单位级别:

三甲医院

Institution/hospital:

Department of Anorectal Surgery the Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine

Level of the institution:

Tertiary Grade A Hospital

测量指标:

Outcomes:

指标中文名:

肛门创缘水肿程度

指标类型:

主要指标

Outcome:

Degree of Anal Wound Edge Edema

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规

指标类型:

次要指标

Outcome:

Complete Blood Count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

创面愈合程度

指标类型:

主要指标

Outcome:

Wound Healing Degree

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肛门坠胀

指标类型:

主要指标

Outcome:

Anal Heaviness or Sensation of Fullness

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能

指标类型:

次要指标

Outcome:

Liver Function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肛门疼痛评分

指标类型:

主要指标

Outcome:

Anal Pain Score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

出血情况

指标类型:

主要指标

Outcome:

Bleeding Condition

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能

指标类型:

次要指标

Outcome:

Renal Function

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

结束

Completed

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用计算机生成的区组随机化序列,由独立统计师(未参与受试者招募及疗效评估)通过SAS 9.4 PROC PLAN程序生成随机分配表。试验组与对照组的比例为1:1。随机序列通过密封不透光信封(急诊研究可采用中央随机系统)实现分配隐藏,由第三方药师或非研究组成员在入组时启封执行分组。

Randomization Procedure (please state who generates the random number sequence and by what method):

This study uses a computer-generated block randomization sequence created by an independent statistician (who was not involved in participant recruitment or efficacy evaluation) using the SAS 9.4 PROC PLAN program to generate the random allocation table. The ratio of the experimental group to the control group is 1:1. The random sequence allocation is concealed using sealed opaque envelopes (for emergency trials a central randomization system may be used) and the group assignment is revealed and implemented by a third-party pharmacist or a non-research team member at the time of enrollment.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用病例记录表(CRF)与电子数据采集系统(EDC)协同管理模式,确保数据完整性及合规性: 1.病例记录表(CRF)采集流程:由研究者依据原始医疗记录(如手术记录、实验室报告)填写纸质CRF,经监查员(CRA)逐项核对后,通过双人独立录入(double data entry)方式转录至电子数据库,录入差异率需低于0.5%。 2.电子数据采集系统(EDC)平台选择:采用基于互联网的ResMan系统(符合21 CFR Part 11及GDPR要求),支持多中心实时数据录入及远程监查。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(CRF)(EDC)

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above